Bile Acids and the Gallbladder

Gut · §53

Your liver makes a detergent called bile; the gallbladder is the small green sack that stores it and squirts a concentrated pulse into the gut when food shows up. Most people never think about any of this — until a gallstone forces the issue or the sack comes out. The surprise then: you can live without a gallbladder, but somewhere between one in twenty and one in ten people develop chronic urgent diarrhoea afterwards, and the cheap fix is a binding powder almost nobody gets offered. The same fix works for a huge slice of people stuck under an IBS label that never quite fit.

Know · As-needed Evidence Moderate Chapter Gut

The reason this entry exists: a meaningful slice of people stuck under an "IBS" label, or with stubborn loose stools after gallbladder removal, actually have bile dripping into the gut between meals instead of pulsing on cue. The colon hates that; a cheap binding powder fixes the day for most of them in under a week. Everyone else can mostly ignore the anatomy until a stone makes them care. Inside the affected group, quality of life sags toward inflammatory-bowel-disease territory — and it doesn't have to.

Bile is the body's dishwasher detergent for fat. The liver makes it continuously out of cholesterol — one of the main reasons your liver matters for cholesterol numbers in the first place — and pipes it down a network of small ducts that converge into one main pipe heading for the small intestine. Between meals the gut doesn't want detergent, so a tiny ring of muscle clamps the main pipe shut and the bile backs up into the gallbladder, where it sits and gets concentrated by a factor of five to ten as the sack reabsorbs water out of it.

Then food arrives. The duodenum — the first stretch of small intestine, just past the stomach — tastes fat and protein and releases a hormone called CCK (cholecystokinin). CCK tells the gallbladder to squeeze and the muscle ring to relax, and a pulse of concentrated bile hits the food bolus on cue. Bile salts swarm fat droplets into microscopic packets called micelles — small enough to bump up against the gut wall and unload their cargo of fatty acids, cholesterol, and the four fat-soluble vitamins (A, D, E, K).

The system is more frugal than it looks. About 95% of the bile that gets released is grabbed back at the end of the small intestine, returned to the liver through the gut's main vein, and re-secreted into the next meal's pulse. The whole pool — only about three grams of bile salts in total — cycles 6–8 times a day, with the liver topping up the small fraction lost in stool Hofmann 2009. And modern biology has added a twist: bile acids aren't only detergents. They're hormones too, talking to receptors in the liver, gut wall, and brown fat about how to handle sugar and energy de Aguiar Vallim et al. 2013.

How often this matters

Gallstones are common. Roughly one in twelve American men and one in six American women either have stones or have already had the gallbladder taken out, with the rate climbing sharply in some populations — Mexican-American women approaching one in three, and several Native American groups higher still Everhart et al. 1999. Most stones do nothing forever; only about one or two percent per year tip into pain. When they do, the standard move is laparoscopic removal of the whole gallbladder — quick, durable, low-risk. Around 700,000–800,000 of these surgeries happen in the US each year EASL 2016.

The interesting number is what happens afterward. Five to twelve percent of cholecystectomy patients develop persistent loose stools — often urgent, often triggered by food — and stay that way for years Sauter et al. 2002 Fisher et al. 2008. The mechanism is straightforward once you see the system. Without a reservoir to pulse bile, the liver drips it continuously into a mostly-empty gut, and between meals the extra bile sails past the absorption point at the end of the small intestine and into the colon, which responds by dumping water and salt into the lumen. Net effect: urgent, watery, post-meal-and-overnight diarrhoea.

The same mechanism — bile-acid spillover into the colon — also drives a stand-alone condition called bile-acid diarrhoea in people who still have a gallbladder. Here the prevalence figure is the real surprise. Across UK and European studies, roughly one in three patients walking around with a diarrhoea-predominant IBS diagnosis turn out to have bile-acid diarrhoea instead Pattni and Walters 2009 Camilleri 2015. Different problem, different mechanism, specific treatment most of them have never been offered.

For the broader gallstone population the longer-term stakes are small but real: gallstones are the dominant risk factor for gallbladder cancer, but the absolute incidence is low enough that prophylactic surgery on people without symptoms isn't recommended outside a few high-risk exceptions EASL 2016. The other end of the bile system — chronic cholestatic liver diseases like primary biliary cholangitis — is rarer still but slower-burning: untreated, it scars the liver toward cirrhosis over years, and standard treatment (ursodeoxycholic acid) substantially modifies the trajectory Lindor et al. 2019.

What untreated bile-acid diarrhoea actually costs

The number worth holding in mind isn't stool frequency, though that's bad — three to ten urgent loose stools a day is typical. It's the geometry of the day. Meals become calculations. Travel narrows to places with bathrooms you trust. The weekday calendar quietly reshapes around being near a door. Nights stop being uninterrupted. Quality-of-life surveys put people in this state at scores comparable to inflammatory bowel disease, with depression and anxiety prevalence tracking the same way Camilleri 2015.

There's a cruel layer on top. Most of these patients have been told for years that they have IBS — which is to say, functional, which is to say, nothing's wrong, you'll have to live with it. The framing alone wears people down. Published series put the average delay from first symptoms to a correct bile-acid-diarrhoea diagnosis at around five years; primary-care recognition is close to zero Pattni and Walters 2009.

If this is you, the move is a binding powder

If you've had your gallbladder out and you're still running loose two or more months later, or you carry an IBS-D label and nobody has tried a bile binder, the next conversation with your doctor is about a class of drugs called bile-acid sequestrants. They're old, cheap, and they work by sitting in the gut and grabbing bile salts before the colon sees them. The colon stops getting irritated; the diarrhoea stops.

Cholestyramine — the classic. A powder mixed into water or juice. Cheap (often under twenty dollars a month generic), gritty, effective. Start around 4 g once a day and titrate up until stools firm up, usually 4 to 16 g a day in divided doses with meals.
Colesevelam — the modern version. Tablets, no grit, fewer drug interactions, easier to live with. More expensive but still moderate (a few hundred dollars a year retail in the US).
Spacing other pills. Take other oral medications at least an hour before or four hours after the sequestrant — thyroid hormone, blood thinners, heart-rhythm drugs, statins, and birth-control pills all get bound up too if they go in at the same time.
Response window. If it's working, you'll notice within 3–7 days. If two weeks of a reasonable dose change nothing, the problem is probably something else.

Dietary fat moderation — spreading fat across smaller meals rather than dumping it all into one steak dinner — helps the subset who don't fully respond, and adds almost no burden. Severe low-fat diets aren't necessary and aren't usually what works Fisher et al. 2008. Soluble fibre does a gentler version of the same job: a daily dose of psyllium mops up bile salts before the colon sees them, a fair add-on or stopgap when a sequestrant isn't to hand.

What changes when it's actually treated

Within the first week of a working dose: stools firm up; the dash-to-the-bathroom reflex after meals goes quiet; nights stop including bathroom trips. Within a month: you start saying yes to things you'd been quietly saying no to — restaurants without scoped-out bathrooms, road trips, longer meetings without a calculation about the next break. The trial and open-label data converge on 70 to 96 percent of bile-acid-diarrhoea patients responding this way to a sequestrant Camilleri 2015 Walters and Pattni 2010.

One detail makes the diagnosis cleaner over time: if you stop the powder, the diarrhoea comes back within days. Restart, it stops again. Most patients confirm the mechanism this way at least once before they fully accept that the answer was this small all along.

When the powder is wrong, or needs care

Sequestrants are constipating; for many people that's the dose-limiting effect, and it's also a useful titration signal. They also bind a long list of other oral drugs in the gut and can quietly under-deliver them. The clinically most-important interactions:

Colesevelam is the cleaner choice if you're juggling several chronic medications — its interaction profile is much narrower than the older powders, and it's the sensible starting point for anyone already on a long pill list Walters and Pattni 2010.

Things people get wrong

"You need a low-fat diet forever after gallbladder removal." Almost nobody does. Most people are back on a normal diet within a few weeks. The minority who stay loose respond better to a binding powder than to severe fat restriction Fisher et al. 2008.
"The gallbladder is vestigial — it does nothing." It does something; you just don't notice the loss most of the time because modern Western meals are intermittently fatty rather than single huge fatty meals. Survivable, not unfelt.
"IBS-D is the diagnosis." For roughly one in three people walking around with diarrhoea-predominant IBS, the actual answer is bile-acid diarrhoea — a different mechanism with a specific, cheap, fast-acting treatment Pattni and Walters 2009 Camilleri 2015.
"Bile is just for digesting fat." Twenty years out of date. Bile acids are also hormones — they tell the liver, the gut, and brown fat how to handle sugar and energy, and an entire pharmacology around them is in active drug development de Aguiar Vallim et al. 2013.

Why this gets missed for years

Three reasons stack. First, the cleanest diagnostic test — a radioactive bile-acid scan called SeHCAT — isn't available in the US at all (the radiolabel was never FDA-approved), and the blood-test alternative isn't ordered routinely. So even doctors who know about bile-acid diarrhoea often can't easily confirm it. Second, the empirical alternative — just trial a binding powder for two weeks and see — is a reasonable diagnostic substitute but is rarely the reflex in primary care, where "IBS, here's a fibre supplement" is the worn path Camilleri 2015. Third, cholestyramine is gritty and unpleasant; patients who were prescribed it without explanation, or without the offer of the tablet alternative, quietly quit, and the chart records it as "didn't work" instead of "didn't try."

If you're the patient, the move is to ask explicitly. "Could this be bile-acid diarrhoea? Can we trial cholestyramine or colesevelam for two weeks?" is a specific, reasonable request that costs almost nothing to test.

Things related you might want to look into

If this opened a door, three adjacent areas carry the next step of the story. The gut microbiome's role in bile chemistry — bacteria modify bile acids in the colon, and those modified forms feed back into liver and immune behaviour — is one of the more active fields in gut research right now. The fat-soluble vitamins (A, D, E, K) have an entry of their own; for anyone with a chronic bile-flow problem like primary biliary cholangitis or sclerosing cholangitis, screening these matters. And the metabolic side of bile acids — the FXR receptor and the drug class built around it — is showing up in liver-disease and diabetes pipelines and is worth knowing exists.

Related in the handbook

Helps

— No binding powder handy? Soluble fibre like psyllium also mops up excess bile acids and can firm up the loose stools.

— Loose, urgent stools (Bristol 6-7) after gallbladder removal are the classic bile-acid pattern.
— Unexplained chronic diarrhoea is often bile acids; a sequestrant fixes it fast.
— A lot of people stuck under an IBS label actually have bile acid diarrhoea — and a cheap powder fixes it.

1. Substance and claimed effects

Bile acids are amphipathic steroids synthesised from cholesterol in hepatocytes (primary: cholic and chenodeoxycholic acid), conjugated with glycine or taurine, secreted into bile, concentrated 5–10× by the gallbladder between meals, and released into the duodenum when cholecystokinin (CCK) signals a fatty meal Hofmann 1999 Russell 2003. They have two roles: detergents that emulsify dietary triglyceride and form mixed micelles enabling absorption of long-chain fatty acids, monoglycerides, cholesterol, and the fat-soluble vitamins A, D, E, K; and signalling molecules acting on the nuclear receptor FXR and the membrane receptor TGR5 to regulate their own synthesis, lipid and glucose homeostasis, and incretin release de Aguiar Vallim et al. 2013 Wahlström et al. 2016. The gallbladder is a reservoir that converts continuous hepatic bile output into a meal-pulsed delivery; it is not strictly necessary for life. The entry covers bile-acid physiology, the gallbladder's reservoir role, gallstone disease, cholecystectomy and its sequelae (post-cholecystectomy diarrhoea, bile-acid diarrhoea), bile-acid sequestrant therapy, and the fat-soluble-vitamin malabsorption that follows severe cholestatic states. Holistic consequences scored: short-term health (chronic diarrhoea in a minority is genuinely life-disrupting and reversible with cheap therapy), mood (chronic post-cholecystectomy diarrhoea has measurable QoL and depression load), energy (fat malabsorption in cholestasis produces fatigue via fat-soluble vitamin deficiency), longevity (gallstones are a risk factor for gallbladder cancer, and chronic cholestasis is associated with cirrhosis), beauty-cumulative (long-standing fat-soluble vitamin deficiency in cholestasis affects skin/vision). Effort and cost burdens are small for the symptomatic minority; near zero for everyone else.

2. Evidence by addressing question

Mechanism

The enterohepatic circulation is the central mechanism: cholesterol → 7α-hydroxylation by CYP7A1 (the rate-limiting step) → primary bile acids → glycine/taurine conjugation → ATP-dependent secretion via BSEP into bile canaliculi → bile ducts → common bile duct Russell 2003 Hofmann 2009. Between meals, the sphincter of Oddi is contracted and bile is diverted to the gallbladder, which actively reabsorbs sodium, chloride, bicarbonate and water across its mucosa, concentrating bile up to tenfold and storing roughly 30–60 mL of viscous, highly concentrated bile Hofmann 1999. A fatty or protein-rich meal arriving in the duodenum triggers CCK release from I-cells; CCK contracts the gallbladder and relaxes the sphincter of Oddi, ejecting a bolus of concentrated bile into the duodenum. Bile salts lower the surface tension of triglyceride droplets, allowing pancreatic lipase to access the substrate, and then incorporate the resulting fatty acids, monoglycerides, cholesterol, and fat-soluble vitamins into mixed micelles (~5 nm aggregates) that shuttle lipid through the unstirred water layer to the enterocyte brush border Hofmann 1999.

Roughly 95% of conjugated bile acids are actively reabsorbed in the terminal ileum via ASBT (the apical sodium-dependent bile-acid transporter), returned to the liver through the portal vein, and re-secreted — the enterohepatic circulation cycles 4–12 times per day. The total bile-acid pool is ~3 g; faecal loss is roughly 200–600 mg/day and is replaced by hepatic synthesis under negative feedback through FXR-induced FGF19 from the ileum, which suppresses CYP7A1 Hofmann 2009 Wahlström et al. 2016. Bile acids that escape ileal reabsorption reach the colon, where bacterial 7α-dehydroxylation produces the secondary bile acids deoxycholic and lithocholic acid. Beyond detergency, bile acids activate FXR (gut and liver, regulating their own synthesis, lipogenesis, and glucose handling) and TGR5 (brown adipose and enteroendocrine L-cells, increasing energy expenditure and GLP-1 release) — bile acids are now understood as hormones as much as detergents de Aguiar Vallim et al. 2013.

The post-cholecystectomy state changes the kinetics, not the chemistry. Without a reservoir, bile dribbles continuously into the duodenum at low concentration rather than arriving as a pulse synchronized with food. Fat digestion remains adequate for typical Western meals, but the bile-acid load reaching the colon between meals (when the duodenal lumen is empty and no fat is present to bind bile salts into micelles) is increased — producing the cholerheic diarrhoea seen in a substantial minority of cholecystectomy patients Sauter et al. 2002 Pattni and Walters 2009.

Evidence

Gallstone disease is common: NHANES III estimated gallstones or prior cholecystectomy in roughly 8.6% of US men and 16.6% of US women aged 20–74, with Mexican-American women approaching 27% and Native American populations far higher Everhart et al. 1999. Around 700,000–800,000 cholecystectomies are performed annually in the United States, mostly laparoscopic for symptomatic cholelithiasis or acute cholecystitis EASL 2016. Asymptomatic stones rarely warrant surgery: the natural-history estimate is roughly 1–2% per year progression to biliary colic over the first decade, and prophylactic cholecystectomy is not recommended outside specific high-risk groups (porcelain gallbladder, gallstones >3 cm, certain Native American populations, transplant candidates) EASL 2016 Portincasa et al. 2006.

Post-cholecystectomy diarrhoea: reported incidence ranges from 5–12% in larger prospective and questionnaire-based series, with bile-acid malabsorption demonstrable by ⁷⁵SeHCAT testing in the majority of these symptomatic patients Sauter et al. 2002 Fisher et al. 2008. Predictors include preoperative diarrhoea, younger age, and shorter operating time (a proxy for milder disease being operated on for marginal indications). Independently of cholecystectomy, primary bile-acid diarrhoea (idiopathic BAD, formerly “type 2”) is the cause of roughly one in three patients carrying a diagnosis of diarrhoea-predominant IBS — a finding with substantial replication in UK and continental European cohorts and effectively no recognition in primary care Pattni and Walters 2009 Camilleri 2015 Walters and Pattni 2010.

Bile-acid sequestrant therapy (cholestyramine, colestipol, colesevelam) produces marked symptom improvement in 70–96% of BAD patients across small randomised and open-label series, with colesevelam better tolerated than the older powders Camilleri 2015 Walters and Pattni 2010. The effect is rapid (days) and dose-titratable. Specificity of the trial-of-therapy is high enough that empirical sequestrant trial is now an acceptable diagnostic substitute for ⁷⁵SeHCAT in centres without access to the test Camilleri 2015.

Fat-soluble vitamin malabsorption from insufficient bile delivery is overwhelmingly a cholestatic-disease problem (primary biliary cholangitis, primary sclerosing cholangitis, biliary atresia in infants, prolonged extrahepatic biliary obstruction), not a post-cholecystectomy one. PBC carries clinically meaningful prevalence of vitamin D, A, and K deficiency in advanced disease; AASLD 2018 guidance recommends fat-soluble vitamin screening and replacement Lindor et al. 2019. Routine post-cholecystectomy patients do not develop fat-soluble vitamin deficiency because bile still flows into the gut continuously; absorption capacity is preserved.

Protocol

For the median reader (no gallbladder issues): no action. The gallbladder is doing its job invisibly; bile acid biology is not actionable except as awareness.

For symptomatic gallstones: laparoscopic cholecystectomy is the standard. UDCA dissolution therapy is reserved for highly selected patients (small cholesterol-only stones, functional gallbladder, contraindication to surgery) and is slow and frequently followed by recurrence after discontinuation EASL 2016. Asymptomatic stones found incidentally — observation, not surgery EASL 2016.

For post-cholecystectomy diarrhoea or suspected primary BAD: empirical bile-acid sequestrant. Cholestyramine 4 g/day starting dose, titrating to symptom control (typical effective dose 4–16 g/day in divided doses with meals). Colesevelam 1.25–3.75 g/day as a tablet form with better tolerability and fewer drug interactions Walters and Pattni 2010. Dietary fat moderation (spreading fat across several smaller meals rather than one large fatty meal) helps the subset who respond poorly to sequestrants and adds little burden. In PBC and other cholestatic disease, UDCA 13–15 mg/kg/day is first-line; fat-soluble vitamin replacement is added when deficiency is documented Lindor et al. 2019.

Contraindications

Cholestyramine and colestipol bind many drugs in the gut lumen — thyroxine, warfarin, digoxin, statins, oral contraceptives, fat-soluble vitamins themselves. Dose other oral medications at least 1 h before or 4 h after the sequestrant. Colesevelam has a substantially narrower interaction profile but still interferes with thyroxine and some glucose-lowering drugs Walters and Pattni 2010. Long-term high-dose sequestrant use can precipitate or worsen fat-soluble vitamin deficiency (especially K — bleeding risk), so monitoring is appropriate for patients on chronic therapy and screening before pregnancy. Sequestrants are constipating; this is the dose-limiting effect for many patients but also useful as a downward titration signal. UDCA in PBC is generally well-tolerated; PSC is a contested indication where high-dose UDCA may worsen outcomes.

Misconceptions

“You need a low-fat diet forever after gallbladder removal.” Not supported by evidence — most patients return to a normal diet within 2–6 weeks. Continuous bile delivery handles typical Western meals adequately; the minority who develop persistent diarrhoea respond better to a bile-acid sequestrant than to severe fat restriction Fisher et al. 2008 Sauter et al. 2002.

“The gallbladder is a vestigial organ.” Wrong framing. It is functionally redundant in adults eating modern intermittently-fatty meals — meaning its loss is survivable, not that it has no function. Carnivores and humans on high-fat single meals would suffer more without it.

“Diarrhoea-IBS is a diagnosis.” In ~30% of patients carrying that label, the actual diagnosis is bile-acid diarrhoea — a different mechanism with a specific, highly effective, cheap treatment that nobody has offered them Pattni and Walters 2009 Camilleri 2015.

“Bile acids are just detergents.” Outdated by 20 years. They are FXR/TGR5 ligands regulating glucose, lipid, and energy metabolism; obeticholic acid (an FXR agonist) is licensed for PBC and was a leading MASH candidate de Aguiar Vallim et al. 2013.

Failure-modes

The dominant failure mode is diagnostic. Bile-acid diarrhoea is mistaken for IBS-D for years on average; UK series report median delays of 5+ years from symptom onset to BAD diagnosis even in tertiary referral settings, with primary-care recognition near zero Pattni and Walters 2009 Camilleri 2015. ⁷⁵SeHCAT testing is unavailable in the United States entirely (the radiolabel is not FDA-approved); diagnosis there relies on empirical sequestrant trial or 7α-hydroxy-4-cholesten-3-one (C4) serum testing, both underused. Patients cycle through low-FODMAP diets, antidiarrhoeals, and IBS pharmacotherapy without a sequestrant trial.

A second failure mode: cholestyramine non-adherence. The powder is gritty, unpalatable, and inconvenient; patients abandon effective therapy because nobody warned them or switched them to colesevelam tablets. A third: drug-interaction iatrogenesis (thyroxine under-replacement, warfarin lability) from co-administered sequestrant + chronic medications.

Audience

Three reader subgroups have actionable content. (1) Post-cholecystectomy patients with persistent diarrhoea, who likely have bile-acid malabsorption and have not been offered a sequestrant trial — population estimate 5–12% of cholecystectomies Sauter et al. 2002 Fisher et al. 2008. (2) IBS-D patients (a far larger pool), of whom ~30% have undiagnosed BAD Camilleri 2015. (3) Patients with PBC, PSC, or other cholestatic liver disease, where fat-soluble vitamin monitoring and UDCA matter Lindor et al. 2019. Demographically, gallstone disease skews female and older; BAD skews neither dramatically.

Alternatives

For symptomatic gallstones, alternatives to cholecystectomy are oral dissolution with UDCA (slow, high recurrence, narrow eligibility), extracorporeal shock-wave lithotripsy (rarely used now), and watchful waiting for mild infrequent symptoms — none competitive with laparoscopic cholecystectomy for typical disease EASL 2016. For BAD, alternatives to sequestrants are FXR agonists (obeticholic acid showed signal in BAD trials but is not licensed for the indication) and the FGF19 axis (under investigation). Loperamide controls symptoms without addressing the mechanism and is reasonable as adjunct.

Stakes

Untreated bile-acid diarrhoea produces 3–10+ urgent loose stools per day, including post-meal and nocturnal, with faecal urgency that constrains where patients will travel or eat. QoL surveys in BAD cohorts show scores comparable to inflammatory bowel disease, with elevated rates of anxiety and depression and substantial work-day loss Camilleri 2015. Years of misdiagnosis as IBS — with the implicit "this is functional, learn to live with it" framing — compound the psychological burden. For the much smaller cholestatic-disease cohort, untreated fat malabsorption produces vitamin D-related bone disease, vitamin K-related bleeding, vitamin A-related night blindness and skin changes, and progressive nutritional deterioration Lindor et al. 2019.

Payoff

For diagnosed BAD on a sequestrant: stool frequency drops within 3–7 days; faecal urgency resolves; meals stop being a calculation. Open-label and small RCT data converge on 70–96% symptomatic response Camilleri 2015 Walters and Pattni 2010. The intervention costs roughly $200–600/year in the US (colesevelam) or far less (generic cholestyramine), is reversible, and stops working immediately on withdrawal — confirming the mechanism each time.

Out-of-scope

Pointers the article will surface briefly: the broader gut microbiome (bacterial deconjugation, secondary bile acid biology); FXR pharmacology (obeticholic acid in PBC and MASH); cholesterol metabolism via the bile-acid route (statins, ezetimibe). Excluded from depth: paediatric biliary atresia (different population, surgical), primary sclerosing cholangitis management (specialist territory), and the bariatric-surgery analogues where bile-acid redirection plausibly drives some of the metabolic benefit.

3. The credibility range

Optimist case

Bile-acid physiology is one of the better-resolved digestive systems in human medicine; the mechanism is textbook and the clinical sequelae are predictable. The strong claim: a substantial fraction of "IBS" is undiagnosed bile-acid diarrhoea, the treatment is a cheap, reversible, fast-acting drug class, and the diagnostic gap is purely a recognition failure. UK guideline bodies and specialist gastroenterology centres broadly accept this; the holdout is generalist primary care. The 70–96% response rate to sequestrants is robust across multiple series, and the absence of ⁷⁵SeHCAT availability in the US has masked rather than refuted the phenomenon. Bile-acid biology as a signalling system (FXR, TGR5, FGF19) opens a credible therapeutic frontier in MASH, T2D, and PBC.

Skeptic case

Many post-cholecystectomy "diarrhoea" complaints are actually loose-stool patterns within normal variation, complicated by recall bias against a remembered pre-surgery baseline. The 30% IBS-as-BAD figure rests on ⁷⁵SeHCAT cutoffs that are not universally agreed and that produce different prevalences in different populations; some of the response to sequestrants may be the constipating side effect rather than mechanism-specific. The trial literature is dominated by small open-label series and observational cohorts; large blinded RCTs are sparse. FXR agonism as a metabolic therapy has had a hard run — obeticholic acid in MASH was withdrawn after the REGENERATE programme; the bile-acid-signalling story has been overhyped relative to delivered drugs.

Author's call

The core physiology is settled and uncontroversial. The clinical claim that 5–12% of cholecystectomy patients develop persistent bile-acid diarrhoea is well-supported and under-acted-on. The claim that ~30% of IBS-D is actually BAD is conservative-true (the real number may be lower in unselected populations than in tertiary-referral series but is non-trivial in either case), and the sequestrant response is real enough that empirical trial is defensible. The signalling biology is real but not yet translating to broad clinical use — covered in the article as context, not as a do-action. evidence high; controversy low except at the margins (signalling pharmacology, diagnostic cutoffs).

4. Stakeholder and incentive map

Surgeons / hospitals. Cholecystectomy is high-volume, lucrative, and durably curative for symptomatic stones. Incentive aligns with appropriate care; no evidence of widespread over-operation in symptomatic disease, but indication creep in marginally symptomatic patients is plausible.
Gastroenterology specialty bodies (BSG, ACG, AGA). Have produced position statements naming BAD as under-diagnosed; have not changed primary-care behaviour. Aligned with diagnosis, less aligned with cheap empirical treatment that reduces referral volume.
Primary care. Time-pressured, IBS-D is a familiar label, sequestrants are not in the usual prescribing reflex. Disincentive against introducing a powder requiring counselling.
Pharma. Generic cholestyramine is cheap and unprofitable; colesevelam is mid-price. FXR agonists (obeticholic acid, others) are the high-stakes territory — strong commercial push around metabolic indications, mixed clinical results.
Patient advocacy. BAD UK and similar groups have driven the recognition agenda; community signal is unusually well-aligned with the specialist position.

5. Population variability

Sex. Gallstone disease is roughly 2× more common in women (oestrogen effects on biliary cholesterol secretion). Post-cholecystectomy diarrhoea incidence is similar across sexes.
Age. Gallstone prevalence rises with each decade; cholecystectomies skew middle-aged to older.
Ethnicity. Native American populations have very high gallstone prevalence (up to 70% in Pima women); Mexican-American higher than non-Hispanic white; Black Americans lower; East Asian populations have higher pigment-stone fraction Everhart et al. 1999.
Body composition. Obesity and rapid weight loss (including post-bariatric) both elevate stone risk; bariatric surgery alters bile-acid kinetics in ways implicated in some of its metabolic benefit.
Cholestatic disease. PBC overwhelmingly affects middle-aged women; PSC skews male and is associated with inflammatory bowel disease. Fat-soluble vitamin deficiency is the specific risk in advanced disease.
Genetic. Rare bile-acid synthesis defects in infants; gallstone susceptibility polymorphisms (ABCG5/8) elevate cholesterol gallstone risk modestly.

6. Knowledge gaps

Three significant gaps. First, the true population prevalence of primary bile-acid diarrhoea outside the IBS-D population is unknown — the figure of ~1% of the general population is an extrapolation, not a measurement. Second, the long-term consequences of decades of cholecystectomy on metabolic disease (T2D, MASH, colorectal cancer through altered secondary bile-acid exposure) are biologically plausible but not robustly established in epidemiology; cohort studies report inconsistent associations. Third, FXR/TGR5 therapeutics outside PBC remain in trial; whether bile-acid-axis drugs will become useful in MASH, T2D, or BAD itself is genuinely open. Smaller gaps: optimal sequestrant dosing and duration; whether empirical sequestrant trial should be the primary-care standard for chronic diarrhoea; the placebo-magnitude floor in dose-titrated open-label trials.

Brief vs delivered. The brief named bile production, gallbladder storage, release into the small intestine, fat digestion, fat-soluble vitamin absorption, stool consistency, and post-cholecystectomy consequences. All are covered. Production/storage/release and fat digestion live in the mechanism section; stool consistency and post-cholecystectomy diarrhoea form the centre of gravity (evidence, stakes, protocol, payoff); fat-soluble vitamin absorption is folded into mechanism, the sequestrant-warning callout (A/D/E/K depletion under long-term high-dose use), and the cholestatic-disease paragraph in evidence.

Editorial centre of gravity. The article leans into the bile-acid-diarrhoea recognition story rather than into textbook physiology because that's where the reader payoff actually lives — a meaningful fraction of readers will recognise themselves or someone close, and the treatment is cheap, fast, reversible, and largely unprescribed. Resisting the textbook impulse meant pulling the BAD prevalence number forward and using sequestrant trial-of-therapy as the action backbone.

Beauty scored 0/0. The cholestatic-disease appearance effects (jaundice, pruritus-related skin damage, vitamin-A deficient skin and night-vision changes) are illness-driven sequelae of severe liver disease rather than effects of the bile system as such — too narrow and too disease-mediated to count.
Sleep scored 0. BAD's nocturnal urgency disrupts sleep, but the effect is downstream of diarrhoea, not a direct sleep effect of the bile system; scoring sleep would double-count health_short_term and mood.
Energy = 1 was borderline. The fatigue load from chronic urgent diarrhoea and from cholestatic fat-soluble-vitamin malabsorption is real but indirect. Score landed at 1 rather than 0 because the affected cohort genuinely feels it; coverage is folded into the stakes QoL framing rather than getting its own paragraph.
Action = know rather than decide / respond. The median reader's outcome here is awareness. Affected readers are coached to ask a specific question and trial a powder — closer to respond — but classifying by the median reader felt right; the protocol callout serves the affected subset directly.

Excluded with reason. Deeper bile-acid signalling pharmacology (FXR/TGR5 agonists, FGF19 analogues, obeticholic acid's MASH story) is referenced but not explored — warrants its own entry once the catalogue has more drug-focused content. Bariatric surgery's bile-acid redirection (plausibly part of its metabolic benefit) was out of scope. Paediatric biliary atresia is a different population and a surgical story. Primary sclerosing cholangitis management is specialist territory and didn't fit the reader-action frame; PBC gets one paragraph.

Future-link candidates. An IBS-D entry; a fat-soluble-vitamins entry; a gut-microbiome entry covering bacterial bile-acid modification; an FXR-agonist / liver-pharmacology entry when written. The related field carries stub ids (fat-soluble-vitamins, ibs-d, fiber-intake) that don't yet resolve — wire when the siblings land.

Diagnostic-test asymmetry. The failure-modes section emphasises the US/EU divergence on ⁷⁵SeHCAT availability because the practical advice (empirical sequestrant trial) flows from it. Non-US reviewers may want the framing tightened to local diagnostic norms.

The "one in three IBS-D is BAD" claim. Well-replicated in UK and continental European referral series Pattni and Walters 2009 Camilleri 2015; less established in unselected US primary-care populations because of the absent SeHCAT test. Called conservative-true in the dossier; the article reports it as "roughly one in three" rather than a firmer "a third" to keep an honest hedge without dilution.